elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Pricing
Log in
Sign up
Home
/
Subjects
/
lutetium-177
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Application
keyword
lutetium-177
RIS
0.006
(Research Intensity Score)
Papers
1106
Top papers
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
2021 · 2750 citations
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
2022 · 249 citations
Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial
2023 · 90 citations
Theranostic Nuclear Medicine with Gallium-68, Lutetium-177, Copper-64/67, Actinium-225, and Lead-212/203 Radionuclides
2023 · 94 citations
Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial
2025 · 38 citations
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
2024 · 60 citations
Pheochromocytoma: an updated scoping review from clinical presentation to management and treatment
2024 · 35 citations
Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials
2023 · 98 citations
Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA
2020 · 275 citations
Newest papers
[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study
2026 · 2 citations
89Zr/177Lu-labeled claudin-6 antibody exhibits effective targeted radiodiagnostic and therapeutic efficacy in gynecological cancers
2026 · 2 citations
PeptideNucleic Acid Probes for Pretargeted Affibody-MediatedDelivery of Cytotoxic Payloads to HER2-Positive Carcinoma
2026
Prognostic Factor Analysis and Nomogram Development in Castration-Resistant Prostate Cancer with Visceral Metastases for Future Radionuclide Therapy Selection
2026
[161Tb]Tb-DOTATATE as a potential treatment option for neuroblastoma
2026
[161Tb]Tb-DOTATATE as a potential treatment option for neuroblastoma
2026
Next-generation anti-DLL3 radiopharmaceuticals targeting high-grade neuroendocrine lung and prostate cancers
2026 · 2 citations
eFAP-51, a novel FAPI dimer with enhanced tumor uptake and retention for theranostic applications
2026
Intratumoral dose heterogeneity promotes adaptive anti-tumor immunity and predicts clinical response to radiopharmaceutical therapy
2026
Browse all papers →
lutetium-177's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
lutetium-177's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link